Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Sickle cell disease in Germany: Early insights from a national registry.

Odame I.

Pediatr Blood Cancer. 2020 Jan 6:e28168. doi: 10.1002/pbc.28168. [Epub ahead of print] No abstract available.

PMID:
31904164
2.

End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S.

Blood Adv. 2019 Dec 10;3(23):4002-4020. doi: 10.1182/bloodadvances.2019000883.

3.

Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings.

Ware RE, Odame I.

Pediatrics. 2019 Oct;144(4). pii: e20191681. doi: 10.1542/peds.2019-1681. Epub 2019 Sep 17. No abstract available.

PMID:
31530718
4.

Exploring the Needs of Adolescents With Sickle Cell Disease to Inform a Digital Self-Management and Transitional Care Program: Qualitative Study.

Kulandaivelu Y, Lalloo C, Ward R, Zempsky WT, Kirby-Allen M, Breakey VR, Odame I, Campbell F, Amaria K, Simpson EA, Nguyen C, George T, Stinson JN.

JMIR Pediatr Parent. 2018 Sep 25;1(2):e11058. doi: 10.2196/11058.

5.

Hydroxycarbamide treatment in children with Sickle Cell Anaemia is associated with more intact white matter integrity: a quantitative MRI study.

Kapustin D, Leung J, Odame I, Williams S, Shroff M, Kassner A.

Br J Haematol. 2019 Oct;187(2):238-245. doi: 10.1111/bjh.16063. Epub 2019 Jun 18.

PMID:
31215028
6.

Sickle cell disease: Reducing the global disease burden.

Mburu J, Odame I.

Int J Lab Hematol. 2019 May;41 Suppl 1:82-88. doi: 10.1111/ijlh.13023. Review.

PMID:
31069977
7.

Impact of a transition program with navigator on loss to follow-up, medication adherence, and appointment attendance in hemoglobinopathies.

Allemang B, Allan K, Johnson C, Cheong M, Cheung P, Odame I, Ward R, Williams S, Mukerji G, Kuo KHM.

Pediatr Blood Cancer. 2019 Aug;66(8):e27781. doi: 10.1002/pbc.27781. Epub 2019 May 2.

PMID:
31045326
8.

Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.

Steele C, Sinski A, Asibey J, Hardy-Dessources MD, Elana G, Brennan C, Odame I, Hoppe C, Geisberg M, Serrao E, Quinn CT.

Am J Hematol. 2019 Jan;94(1):39-45. doi: 10.1002/ajh.25305. Epub 2018 Oct 31.

9.

Rhesus disease: a global prevention strategy.

Zipursky A, Bhutani VK, Odame I.

Lancet Child Adolesc Health. 2018 Jul;2(7):536-542. doi: 10.1016/S2352-4642(18)30071-3. Epub 2018 Apr 20.

PMID:
30169325
10.

Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline.

Compernolle V, Chou ST, Tanael S, Savage W, Howard J, Josephson CD, Odame I, Hogan C, Denomme G, Shehata N; International Collaboration for Transfusion Medicine Guidelines.

Transfusion. 2018 Jun;58(6):1555-1566. doi: 10.1111/trf.14611. Epub 2018 Apr 26. Review.

PMID:
29697146
11.

Access to hematopoietic stem cell transplant for patients with sickle cell anemia.

Meier ER, Johnson T, Pinkney K, Velez MC, Kamani N, Odame I.

Pediatr Blood Cancer. 2018 Sep;65(9):e27105. doi: 10.1002/pbc.27105. Epub 2018 Apr 25. Review.

PMID:
29693782
12.

Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis.

Amid A, Chen S, Athale U, Charpentier K, Merelles-Pulcini M, Odame I, Kirby-Allen M.

Haematologica. 2018 May;103(5):e184-e187. doi: 10.3324/haematol.2017.178368. Epub 2018 Jan 25. No abstract available.

13.

Hydroxyurea for SCA in Africa: no malaria harm.

Odame I.

Blood. 2017 Dec 14;130(24):2575-2576. doi: 10.1182/blood-2017-10-812974. No abstract available.

PMID:
29242203
14.

Assessment of cerebral blood flow with magnetic resonance imaging in children with sickle cell disease: A quantitative comparison with transcranial Doppler ultrasonography.

Croal PL, Leung J, Kosinski P, Shroff M, Odame I, Kassner A.

Brain Behav. 2017 Oct 14;7(11):e00811. doi: 10.1002/brb3.811. eCollection 2017 Nov.

15.

Association of wheeze with lung function decline in children with sickle cell disease.

Bendiak GN, Mateos-Corral D, Sallam A, Atenafu EG, Kirby M, Odame I, Bikangaga P, Subbarao P, Grasemann H.

Eur Respir J. 2017 Nov 30;50(5). pii: 1602433. doi: 10.1183/13993003.02433-2016. Print 2017 Nov. No abstract available.

16.

Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia.

McLaren A, Klingel M, Behera S, Odame I, Kirby-Allen M, Grasemann H.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):689-691. doi: 10.1164/rccm.201606-1119LE. No abstract available.

PMID:
28248149
17.

The severity of anaemia depletes cerebrovascular dilatory reserve in children with sickle cell disease: a quantitative magnetic resonance imaging study.

Kosinski PD, Croal PL, Leung J, Williams S, Odame I, Hare GM, Shroff M, Kassner A.

Br J Haematol. 2017 Jan;176(2):280-287. doi: 10.1111/bjh.14424. Epub 2016 Dec 1.

PMID:
27905100
18.

Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M, Odame I, Little JA, Gurkan UA.

Expert Rev Med Devices. 2016 Dec;13(12):1073-1093. Epub 2016 Nov 22. Review.

19.

Managing sickle cell carrier results generated through newborn screening in Ontario: a precedent-setting policy story.

Hayeems RZ, Moore Hepburn C, Chakraborty P, Odame I, Clarke J, Miller FA, Brown AD.

Genet Med. 2017 Jun;19(6):625-627. doi: 10.1038/gim.2016.162. Epub 2016 Oct 20. No abstract available.

PMID:
27763632
20.

Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis.

Amid A, Chen S, Brien W, Kirby-Allen M, Odame I.

Blood. 2016 Mar 3;127(9):1208-11. doi: 10.1182/blood-2015-10-673889. Epub 2016 Jan 5. No abstract available.

PMID:
26732098
21.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Lancet. 2016 Feb 13;387(10019):661-70. doi: 10.1016/S0140-6736(15)01041-7. Epub 2015 Dec 6.

22.

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.

McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T, Aygun B, Obaro SK, Olupot-Olupot P, Williams TN, Odame I, Ware RE; REACH Investigators.

Pediatr Blood Cancer. 2016 Jan;63(1):98-104. doi: 10.1002/pbc.25705. Epub 2015 Aug 14.

23.

Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.

Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE; TWiTCH Investigators.

Am J Hematol. 2015 Sep;90(9):806-10. doi: 10.1002/ajh.24089.

24.

Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.

Narang I, Kadmon G, Lai D, Dhanju S, Kirby-Allen M, Odame I, Amin R, Lu Z, Al-Saleh S.

Ann Am Thorac Soc. 2015 Jul;12(7):1044-9. doi: 10.1513/AnnalsATS.201410-473OC.

PMID:
25970812
25.

Hb S/β+-thalassemia due to Hb sickle and a novel deletion of DNase I hypersensitive sites HS3 and HS4 of the β locus control region.

Amid A, Cheong M, Eng B, Hanna M, Hohenadel BA, Nakamura LM, Walker L, Odame I, Kirby-Allen M, Waye JS.

Haematologica. 2015 May;100(5):e166-8. doi: 10.3324/haematol.2014.117408. Epub 2015 Feb 14. No abstract available.

26.

Perspective: we need a global solution.

Odame I.

Nature. 2014 Nov 13;515(7526):S10. doi: 10.1038/515S10a. No abstract available.

PMID:
25390135
27.

Improving outcomes in children with sickle cell disease: treatment considerations and strategies.

Amid A, Odame I.

Paediatr Drugs. 2014 Aug;16(4):255-66. doi: 10.1007/s40272-014-0074-4. Review.

PMID:
24797542
28.

Transient erythroblastopenia of childhood is an underdiagnosed and self-limiting disease.

van den Akker M, Dror Y, Odame I.

Acta Paediatr. 2014 Jul;103(7):e288-94. doi: 10.1111/apa.12634. Epub 2014 Apr 29.

PMID:
24635829
29.

Morphine is associated with acute chest syndrome in children hospitalized with sickle cell disease.

Birken CS, Khambalia A, Dupuis A, Pastor A, Lee M, Padavattan K, Mekky M, Odame I, Parkin PC.

Hosp Pediatr. 2013 Apr;3(2):149-55.

30.

Predictors of bacteremia among children with sickle cell disease presenting with fever.

Savlov D, Beck CE, DeGroot J, Odame I, Friedman JN.

J Pediatr Hematol Oncol. 2014 Jul;36(5):384-8. doi: 10.1097/MPH.0000000000000070.

PMID:
24309605
31.

Thermal pain and sensory processing in children with sickle cell disease.

O'Leary JD, Crawford MW, Odame I, Shorten GD, McGrath PA.

Clin J Pain. 2014 Mar;30(3):244-50. doi: 10.1097/AJP.0b013e318292a38e.

PMID:
23629596
32.

Effectiveness of preoperative screening for sickle cell disease in a population with a newborn screening program: a cohort study.

O'Leary JD, Odame I, Pehora C, Chakraborty P, Crawford MW.

Can J Anaesth. 2013 Jan;60(1):54-9. doi: 10.1007/s12630-012-9807-4. Epub 2012 Oct 27.

PMID:
23104576
33.

The Jamaican historical experience of the impact of educational interventions on sickle cell disease child mortality.

Grosse SD, Atrash HK, Odame I, Amendah D, Piel FB, Williams TN.

Am J Prev Med. 2012 Jun;42(6):e101-3. doi: 10.1016/j.amepre.2012.03.005. No abstract available.

34.

Inadequate dietary intake in patients with thalassemia.

Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP; Thalassemia Clinical Research Network.

J Acad Nutr Diet. 2012 Jul;112(7):980-90. doi: 10.1016/j.jand.2012.01.017. Epub 2012 May 1.

35.

A global perspective on sickle cell disease.

Aygun B, Odame I.

Pediatr Blood Cancer. 2012 Aug;59(2):386-90. doi: 10.1002/pbc.24175. Epub 2012 Apr 25. Review.

PMID:
22535620
36.

Liver iron overload assessment by T *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study.

Cheng HL, Holowka S, Moineddin R, Odame I.

Am J Hematol. 2012 Apr;87(4):435-7. doi: 10.1002/ajh.23114. Epub 2012 Jan 28. No abstract available.

37.

Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network.

Blood. 2012 Mar 22;119(12):2746-53. doi: 10.1182/blood-2011-04-344507. Epub 2012 Jan 25.

38.

Concerted global effort to combat sickle cell disease: the first global congress on sickle cell disease in Accra, Ghana.

Odame I, Kulkarni R, Ohene-Frempong K.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S417-21. doi: 10.1016/j.amepre.2011.09.019.

PMID:
22099367
39.

Sickle cell disease in Africa: a neglected cause of early childhood mortality.

Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405. doi: 10.1016/j.amepre.2011.09.013.

40.

Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations.

Tsangaris E, Klaassen R, Fernandez CV, Yanofsky R, Shereck E, Champagne J, Silva M, Lipton JH, Brossard J, Michon B, Abish S, Steele M, Ali K, Dower N, Athale U, Jardine L, Hand JP, Odame I, Canning P, Allen C, Carcao M, Beyene J, Roifman CM, Dror Y.

J Med Genet. 2011 Sep;48(9):618-28. doi: 10.1136/jmg.2011.089821. Epub 2011 Jun 9. Erratum in: J Med Genet. 2012 Sep;49(9):597.

PMID:
21659346
41.

White matter integrity and core cognitive function in children diagnosed with sickle cell disease.

Scantlebury N, Mabbott D, Janzen L, Rockel C, Widjaja E, Jones G, Kirby M, Odame I.

J Pediatr Hematol Oncol. 2011 Apr;33(3):163-71. doi: 10.1097/MPH.0b013e3182036f33.

PMID:
21325970
42.

Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin.

Odame I.

Am J Prev Med. 2010 Apr;38(4 Suppl):S571-5. doi: 10.1016/j.amepre.2009.12.021.

PMID:
20331960
43.

Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies.

Athale UH, Duckworth J, Odame I, Barr R.

J Pediatr Hematol Oncol. 2009 Sep;31(9):651-63. doi: 10.1097/MPH.0b013e3181b258a9.

PMID:
19707161
44.

Accurate liver T2 measurement of iron overload: a simulations investigation and in vivo study.

Beaumont M, Odame I, Babyn PS, Vidarsson L, Kirby-Allen M, Cheng HL.

J Magn Reson Imaging. 2009 Aug;30(2):313-20. doi: 10.1002/jmri.21835.

PMID:
19629985
45.

A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.

Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E.

Eur J Cancer. 2009 Sep;45(13):2352-9. doi: 10.1016/j.ejca.2009.05.008. Epub 2009 Jun 6.

PMID:
19505817
46.

Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A.

Macartney C, Freilich M, Odame I, Charpentier K, Dror Y.

Pediatr Blood Cancer. 2009 Apr;52(4):525-7. doi: 10.1002/pbc.21751.

PMID:
19058202
47.

Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes.

Teo JT, Klaassen R, Fernandez CV, Yanofsky R, Wu J, Champagne J, Silva M, Lipton JH, Brossard J, Samson Y, Abish S, Steele M, Ali K, Athale U, Jardine L, Hand JP, Tsangaris E, Odame I, Beyene J, Dror Y.

Pediatrics. 2008 Jul;122(1):e139-48. doi: 10.1542/peds.2007-3415.

PMID:
18595958
48.

Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.

Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, Silva M, Odame I, Mpofu C, Strother D, Bouffet E.

Cancer. 2008 Feb 15;112(4):892-9.

49.

Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report.

Johnston DL, Keene DL, Lafay-Cousin L, Steinbok P, Sung L, Carret AS, Crooks B, Strother D, Wilson B, Odame I, Eisenstat DD, Mpofu C, Zelcer S, Huang A, Bouffet E.

J Neurooncol. 2008 Jan;86(1):101-8. Epub 2007 Jul 10.

PMID:
17619825
50.

Childhood meningitis at King Fahad Hospital, Hofuf, Saudi Arabia.

Laditan AA, Odame I, Ogundipe O.

Ann Saudi Med. 1997 Nov;17(6):605-8.

Supplemental Content

Support Center